GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » Sloan Ratio %

Heska (HSKA) Sloan Ratio % : 3.67% (As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Heska Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Heska's Sloan Ratio for the quarter that ended in Mar. 2023 was 3.67%.

As of Mar. 2023, Heska has a Sloan Ratio of 3.67%, indicating the company is in the safe zone and there is no funny business with accruals.


Heska Sloan Ratio % Historical Data

The historical data trend for Heska's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heska Sloan Ratio % Chart

Heska Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.03 -1.16 28.22 4.57 6.43

Heska Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.55 8.87 6.51 6.43 3.67

Competitive Comparison of Heska's Sloan Ratio %

For the Medical Devices subindustry, Heska's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heska's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heska's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Heska's Sloan Ratio % falls into.



Heska Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Heska's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(-19.889--21.813
--35.77)/585.816
=6.43%

Heska's Sloan Ratio for the quarter that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2023 )
=(-20.028--13.309
--28.485)/592.715
=3.67%

Heska's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was -5.246 (Jun. 2022 ) + -0.436 (Sep. 2022 ) + -4.221 (Dec. 2022 ) + -10.125 (Mar. 2023 ) = $-20.0 Mil.
Heska's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was 1.051 (Jun. 2022 ) + -2.037 (Sep. 2022 ) + -3.162 (Dec. 2022 ) + -9.161 (Mar. 2023 ) = $-13.3 Mil.
Heska's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was -0.759 (Jun. 2022 ) + -4.654 (Sep. 2022 ) + -0.514 (Dec. 2022 ) + -22.558 (Mar. 2023 ) = $-28.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heska  (NAS:HSKA) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2023, Heska has a Sloan Ratio of 3.67%, indicating the company is in the safe zone and there is no funny business with accruals.


Heska Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Heska's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Heska (HSKA) Business Description

Traded in Other Exchanges
N/A
Address
3760 Rocky Mountain Avenue, Loveland, CO, USA, 80538
Heska Corp is engaged in developing, manufacturing, marketing, selling, and supporting veterinary products. The company's products include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products; and practice information management software and related software. It operates through two segments North America and International. The Company's core strategic focus on Point of Care laboratory and imaging products is included in both segments.
Executives
Joachim A. Hasenmaier director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Robert L Antin director
Mark F Furlong director 770 M WATER ST, MILWAUKEE WI 53202
Stephen L Davis director 2901 BUTTERFIELD ROAD, OAK BROOK IL 60523
Providenti Anthony C. Jr. officer: EVP, Corporate Development 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Kevin S. Wilson officer: President and COO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Eleanor F. Baker officer: EVP, Managing Dir. & COO, scil 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Christopher D. Sveen officer: CAO & General Counsel 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Nancy Wisnewski officer: EVP, Prod. Dev. & Cust. Supp 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Sharon L. Riley director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Catherine Grassman officer: EVP, CFO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason D Aroesty officer: EVP, International Diagnostics 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Bonnie J. Trowbridge director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Scott Humphrey director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason A Napolitano officer: Exec. VP, CFO & Secretary 1613 PROSPECT PARKWAY, FORT COLLINS CO 80525